Patents by Inventor Massimo Nabissi

Massimo Nabissi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF PHYTOCANNABINOIDS FOR TREATING MULTIPLE MYELOMA
    Publication number: 20230233583
    Abstract: The present disclosure relates to the use of suitable phytocannabinoids such as cannabidivarin, cannabinol, cannabigerol or cannabichromene or combinations thereof for treatment of multiple myeloma and/or similar conditions, diseases or disorders.
    Type: Application
    Filed: June 11, 2021
    Publication date: July 27, 2023
    Inventors: Massimo Nabissi, Oliviero Marinelli, Cristina Aguzzi, Laura Zeppa, Sazzad Hossain
  • Use of cannabinoids in the treatment of multiple myeloma
    Patent number: 11065227
    Abstract: The present invention relates to the use of a combination of tetrahydrocannabinol (THC) and cannabidiol (CBD) in the treatment of multiple myeloma. The combination of THC and CBD appears to be particularly effective in reducing cell viability and cell migration in this disease. Preferably the THC and CBD are used is in the form of a highly purified extract of cannabis such that the cannabinoids are present at greater than 98% of the total extract (w/w) and the other components of the extract are characterised. Alternatively, the THC and CBD may be a synthetically produced cannabinoid.
    Type: Grant
    Filed: July 31, 2017
    Date of Patent: July 20, 2021
    Assignee: GW Research Limited
    Inventors: Colin Stott, Massimo Nabissi
  • USE OF CANNABINOIDS IN THE TREATMENT OF MULTIPLE MYELOMA
    Publication number: 20190175547
    Abstract: The present invention relates to the use of a combination of tetrahydrocannabinol (THC) and cannabidiol (CBD) in the treatment of multiple myeloma. The combination of THC and CBD appears to be particularly effective in reducing cell viability and cell migration in this disease. Preferably the THC and CBD are used is in the form of a highly purified extract of cannabis such that the cannabinoids are present at greater than 98% of the total extract (w/w) and the other components of the extract are characterised. Alternatively, the THC and CBD may be a synthetically produced cannabinoid.
    Type: Application
    Filed: July 31, 2017
    Publication date: June 13, 2019
    Inventors: Colin STOTT, Massimo NABISSI
  • Use of substance P antagonists in the treatment of the adenocarcinomas
    Patent number: 6576638
    Abstract: It is described the use of antagonists of neuro kynin receptors (NK-1; substance P receptors) in order to establish a new drug effective in the treatment of adenocarcinomas, such antagonists being one or more substances selected among those ones having the following features: pA2>6.0 both in human and in murine tissues, etherocyclic non peptidergic structures, antiangiogenic effects experimentally demonstrated onto the genito-urinary tract rumors induced via orthotopic drafts of human tumoral cells either in the genito-urinary apparatus of either immunodeficient rats or mice, decrease of the tumoral mass on tumors of the genito-urinary tract induced by orthotopic drafts of tumoral cells onto tissues of the genito-urinary tract of either immunodeficient rats or mice.
    Type: Grant
    Filed: May 13, 2002
    Date of Patent: June 10, 2003
    Assignee: Biopolis S.p.A.
    Inventors: Pierluigi Pompei, Maurizio Massi, Massimo Nabissi, Pier Luigi Sparapani